Roche Holding AG Participation (RHHVF) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Roche Holding AG Participation stock forecast from 0 analysts, the average analyst target price for Roche Holding AG Participation is not available over the next 12 months. Roche Holding AG Participation’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Roche Holding AG Participation is Slightly Bearish, which is based on 7 positive signals and 9 negative signals. At the last closing, Roche Holding AG Participation’s stock price was USD 315.00. Roche Holding AG Participation’s stock price has changed by +1.76% over the past week, +11.70% over the past month and +15.13% over the last year.
No recent analyst target price found for Roche Holding AG Participation
No recent average analyst rating found for Roche Holding AG Participation
Company Overview Roche Holding AG Participation
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland. Read Less
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia...Read More
Frequently Asked Questions About Roche Holding AG Participation (RHHVF) Stock
Stock Target Advisor's fundamental analysis for Roche Holding AG Participation's stock is Slightly Bearish.
RHHVF stock's dividend yield is 3.47%.
Our analysis grades RHHVF stock's dividend yield at F. This means that RHHVF stock's dividend yield is above 53% of the stocks in the Drug Manufacturers - General sector in the OTC exchange.
Based on this RHHVF may be a average dividend stock for its sector.
Unfortunately we do not have enough data on RHHVF's stock to indicate what its average analyst target is.
RHHVF stock's Price/Earning ratio is 21.41.
Our analysis grades RHHVF stock's Price / Earning ratio at F. This means that RHHVF stock's Price/Earning ratio is above 41% of the stocks in the Drug Manufacturers - General sector in the OTC exchange.
Based on this RHHVF may be fairly valued for its sector
The last closing price of RHHVF's stock was USD 315.00.
The most recent market capitalization for RHHVF is USD 252.53B.
Unfortunately we do not have enough analyst data on RHHVF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Roche Holding AG Participation's stock.
As per our most recent records Roche Holding AG Participation has 103,605 Employees.
Roche Holding AG Participation's registered address is Grenzacherstrasse 124, Basel, Switzerland, 4058.
You can get more information about it from Roche Holding AG Participation's website at https://www.roche.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Roche Holding AG Participation (RHHVF) Stock
Stock Target Advisor's fundamental analysis for Roche Holding AG Participation's stock is Slightly Bearish.
RHHVF stock's dividend yield is 3.47%.
Our analysis grades RHHVF stock's dividend yield at F. This means that RHHVF stock's dividend yield is above 53% of the stocks in the Drug Manufacturers - General sector in the OTC exchange.
Based on this RHHVF may be a average dividend stock for its sector.
Unfortunately we do not have enough data on RHHVF's stock to indicate what its average analyst target is.
RHHVF stock's Price/Earning ratio is 21.41.
Our analysis grades RHHVF stock's Price / Earning ratio at F. This means that RHHVF stock's Price/Earning ratio is above 41% of the stocks in the Drug Manufacturers - General sector in the OTC exchange.
Based on this RHHVF may be fairly valued for its sector
The last closing price of RHHVF's stock was USD 315.00.
The most recent market capitalization for RHHVF is USD 252.53B.
Unfortunately we do not have enough analyst data on RHHVF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Roche Holding AG Participation's stock.
As per our most recent records Roche Holding AG Participation has 103,605 Employees.
Roche Holding AG Participation's registered address is Grenzacherstrasse 124, Basel, Switzerland, 4058.
You can get more information about it from Roche Holding AG Participation's website at https://www.roche.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RHHVF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
